Patterns of relapse and modalities of treatment of breast cancer: The 'IRIS' project, a multicenter observational study

Oncology

Volumn 66, Issue 4, 2004, Pages 260-268

  Cazzaniga, M ^a   Pronzato, P ^d   Leto Di Priolo, S L ^b   De Matteis, A ^c   Di Costanzo, F ^e   Passalacqua, R ^f   Rosso, R ^g   Torri, V ^h  

^a TREVIGLIO HOSPITAL   (Italy)

^b Link Italia Srl   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d Felettino Hospital   (Italy)

^e CAREGGI UNIVERSITY HOSPITAL   (Italy)

^f CREMONA HOSPITAL   (Italy)

^g UNIVERSITY OF GENOA   (Italy)

^h MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Breast cancer; Follow up; Relapse

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; FLUOROURACIL; FORMESTANE; LETROZOLE; METHOTREXATE; NAVELBINE; PROGESTERONE DERIVATIVE; TAMOXIFEN; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTECTOMY; METASTASIS; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; EDUCATIONAL STATUS; EMPLOYMENT; FEMALE; HUMANS; ITALY; MARITAL STATUS; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; TAXOIDS; TUMOR MARKERS, BIOLOGICAL;

EID: 3042588089     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000078325     Document Type: Article

References (25)

1. Piccart M: Early breast cancer. Eur J Cancer 2001;37(supp 7):S3.
2. Paci E, Quaglia A, Pannelli F, et al: The impact of screening and early diagnosis on survival - Results from the Italian cancer registries. Epidemiol Prev 2001;25:1-375.
3. Balducci L, Extermann M, Carreca I: Management of breast cancer in older women. Cancer Control 2001;8:431-441.
4. Bernhard J, Hurny C, Coates AS, et al: Factors affecting baseline quality of life in two international adjuvant breast cancer trials. International Breast Cancer Study Group (IBCSG). Br J Cancer 1998;78:686-693.
5. Espie M: Breast cancer: New therapeutic strategies. Presse Med 1998;27:2049-2054.
6. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 1998;351:1451-1467.
7. Dombernowsky P, Smith I, Falkson G, et al: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998;16:453-461.
8. Buzdar AU: A summary of second-line randomized studies of aromatase inhibitors. J Steroid Biochem Mol Biol 2001;79:109-114.
9. Hamilton A, Piccart M: The third-generation non-steroidal aromatase inhibitors: A review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. Ann Oncol 1999;10:377-384.
10. Mouridsen H, Gershanovich M, Sun Y, et al: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19:2596-2606.
11. Bonneterre J, Buzdar AU, Nabholtz JM, et al: Anastrozole is superior to tamoxifen as firstline therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001;92:2247-2258.
12. Official Italian Census 2001: STAT, 2002.
13. American Joint Committe on Cancer: Cancer Staging Manual, ed 5. Philadelphia-New York, Lippincot-Raven, 1997.
14. Okken MM: Karnofsky performance status. Am J Clin Oncol 1982;5:649-655.
15. Dunst J, Steil B, Furch S, et al: Prognostic significance of local recurrence in breast cancer after postmastectomy radiotherapy. Strahlenther Onkol 2001;177:504-510.
16. Alba E, Ribelles N, Sevilla I, et al: Adjuvant anthracycline therapy as a prognostic factor in metastatic breast cancer. Breast Cancer Res Treat 2001;66:33-39.
17. Kader H-A, Jackson J, Mates D, et al: Tubular carcinoma of the breast: A population-based study of nodal metastases at presentation and of patterns of relapse. Breast J 2001;7:8-13.
18. National Institutes of Health Consensus Development Panel: National Institutes of Health Consensus Development Conference statement: Adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst Monogr 2001;30:5-15.
19. Love RR: Meeting highlights: International consensus panel on the treatment of primary breast cancer. J Clin Oncol 2002;20:1955-1957.
20. Holly K, Hakama M: Effectiveness of routine and spontaneous follow-up visits for breast cancer. Eur J Cancer 1989;25:251-254.
21. Kindler M, Steinhoff G: Follow-up of breast cancer patients. Oncology 1989;46:360-365.
22. Rosselli del Turco M, Palli D, Cariddi A: Intensive diagnostic follow-up after treatment of primary breast cancer: A randomized trial. JAMA 1994;271:1593-1597.
23. Liberati A, Grilli R: Consensus Conference italiana sul follow-up nel carcinoma della mammella. Fed Med 1995;3:35-40.
24. Smith TJ, Heddinger S: Medically Appropriate Follow-Up of Breast and Lung Cancer Patients. 2002 Educational Book. American Society of Clinical Oncology, 2002, pp 652-657.
25. Rose C: A comparison of the efficacy of aromatase inhibitors in second line treatment of metastatic breast cancer. Am J Clin Oncol 2003;26:S9-S16.